PE20141359A1 - Compuestos y metodos para mejorar las respuestas inmunitarias innatas - Google Patents

Compuestos y metodos para mejorar las respuestas inmunitarias innatas

Info

Publication number
PE20141359A1
PE20141359A1 PE2014000559A PE2014000559A PE20141359A1 PE 20141359 A1 PE20141359 A1 PE 20141359A1 PE 2014000559 A PE2014000559 A PE 2014000559A PE 2014000559 A PE2014000559 A PE 2014000559A PE 20141359 A1 PE20141359 A1 PE 20141359A1
Authority
PE
Peru
Prior art keywords
compounds
alkyl
methods
immune responses
innate immune
Prior art date
Application number
PE2014000559A
Other languages
English (en)
Inventor
Anna Lindsey Banka
Janos Botyanszki
Eric Gregory Burroughs
John George Catalano
Wendy Huang Chern
Hamilton D Dickson
Margaret J Gartland
Robert Hamatake
Hans Hofland
Jesse Daniel Keicher
Christopher Brooks Moore
John Bradford Shotwell
Matthew David Tallant
Jean-Philippe Therrien
Shihyun You
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of PE20141359A1 publication Critical patent/PE20141359A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE X1, X4, X7 Y X8 SON CADA UNO N, NH, S, O, C, CH O CH2; X2, X3, X5 Y X6 SON CADA UNO N, C O CH; Z ES UN ENLACE, -C(O) O ALQUILENO(C1-C6); R1 ES H, HALOGENO, ENTRE OTROS; R2 ES H, ALQUILO(C1-C6), ALCOXILO(C1-C6), ENTRE OTROS; R3 ES H, ALCOXILO(C1-C6), SULFONAMIDA, ENTRE OTROS; R4 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C12), ENTRE OTROS; R5 ES H, HALOGENO, NITRILO, ENTRE OTROS; R6 ES H, ALQUILO(C1-C6), ARILO(C4-C14), ENTRE OTROS; R7 ES H, ALQUILO(C1-C6), NITRILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-[2,4-BIS-(TRIFLUORO-METIL)-IMIDAZO[1,2-a]1,8-NAFTIRIDIN-8-IL]-1,3,4-OXADIAZOL; 2-[2-CICLOPENTIL-4-(TRIFLUORO-METIL)-IMIDAZO[1,2-a]1,8-NAFTIRIDIN-8-IL]-1,3,4-OXADIAZOL; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON POTENCIADORES DE LA RESPUESTA INMUNITARIA SIENDO UTILES EN EL TRATAMIENTO DE INFECCIONES VIRALES
PE2014000559A 2011-10-21 2012-10-19 Compuestos y metodos para mejorar las respuestas inmunitarias innatas PE20141359A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549784P 2011-10-21 2011-10-21
US201261692431P 2012-08-23 2012-08-23

Publications (1)

Publication Number Publication Date
PE20141359A1 true PE20141359A1 (es) 2014-10-13

Family

ID=48141628

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000559A PE20141359A1 (es) 2011-10-21 2012-10-19 Compuestos y metodos para mejorar las respuestas inmunitarias innatas

Country Status (22)

Country Link
US (1) US20140249143A1 (es)
EP (1) EP2768506A4 (es)
JP (1) JP2014532626A (es)
KR (1) KR20140094559A (es)
CN (1) CN103957910A (es)
AR (1) AR088793A1 (es)
AU (1) AU2012325971B2 (es)
BR (1) BR112014008727A2 (es)
CA (1) CA2851801A1 (es)
CL (1) CL2014001016A1 (es)
CO (1) CO6910198A2 (es)
CR (1) CR20140175A (es)
DO (1) DOP2014000081A (es)
EA (1) EA201490610A1 (es)
IL (1) IL231894A0 (es)
MX (1) MX2014004814A (es)
PE (1) PE20141359A1 (es)
SG (2) SG11201400988SA (es)
TW (2) TW201333003A (es)
UY (1) UY34406A (es)
WO (1) WO2013059559A2 (es)
ZA (1) ZA201402392B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333168B (zh) * 2013-07-23 2015-08-05 清华大学 一种酰胺类化合物及其制备方法与应用
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
US10112895B2 (en) 2014-09-29 2018-10-30 The Trustees Of The University Of Pennsylvania Antivirals against molluscum contagiosum virus
CN104529893B (zh) * 2014-12-30 2016-08-24 中国科学技术大学 一类可以作为高尔基体细胞器探针的喹啉染料
CN105175277B (zh) * 2015-05-18 2018-04-03 中山大学肿瘤防治中心 一种3‑磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用
WO2018043747A1 (ja) * 2016-09-05 2018-03-08 国立大学法人京都大学 抗ｂ型肝炎ウイルス剤
JP2020512975A (ja) 2017-03-28 2020-04-30 ピメラ，インク． Ｐｏｌ１阻害剤の新規な結晶形態
KR20210082473A (ko) 2018-10-23 2021-07-05 바스프 에스이 트리시클릭 살충 화합물
CN114681472B (zh) * 2019-03-13 2023-06-30 中国人民解放军军事科学院军事医学研究院 氨基葡萄糖及其衍生物作为抗病毒药物的应用
EP4136086A1 (en) 2020-04-14 2023-02-22 Basf Se Tricyclic pesticidal compounds
WO2022049521A1 (en) * 2020-09-03 2022-03-10 Glaxosmithkline Intellectual Property Development Limited Imidazonaphthyridines and imidazopyridopyrimidines as ifnar2 agonists for treating sars-cov-2 infections
WO2022175425A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Intellectual Property Development Limited Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
WO2023056421A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
KR20240101561A (ko) 2021-10-14 2024-07-02 인사이트 코포레이션 Kras의 저해제로서의 퀴놀린 화합물
WO2023244672A1 (en) 2022-06-14 2023-12-21 Assembly Biosciences, Inc. 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE441449B (sv) * 1979-02-09 1985-10-07 Roussel Uclaf Heterocykliska derivat och farmaceutiska kompositioner innehallande dessa derivat
US4492697A (en) * 1983-08-16 1985-01-08 Ayerst, Mckenna & Harrison, Inc. 4H-Imidazo[2,3-c]pyrido[2,3-e][1,4]oxazine derivatives
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
KR100656205B1 (ko) * 2002-04-03 2006-12-12 에프. 호프만-라 로슈 아게 이미다조 융합 화합물
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
CN102365816B (zh) * 2009-03-31 2015-06-24 大金工业株式会社 高分子致动器元件用电极膜和具有其的高分子致动器元件
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB201002409D0 (en) * 2010-02-12 2010-03-31 Univ Nottingham Methods

Also Published As

Publication number Publication date
EA201490610A1 (ru) 2014-09-30
CO6910198A2 (es) 2014-03-31
ZA201402392B (en) 2017-09-27
TW201333003A (zh) 2013-08-16
JP2014532626A (ja) 2014-12-08
CL2014001016A1 (es) 2015-01-16
US20140249143A1 (en) 2014-09-04
SG11201400988SA (en) 2014-07-30
CR20140175A (es) 2014-06-03
SG10201505664WA (en) 2015-09-29
MX2014004814A (es) 2014-05-27
KR20140094559A (ko) 2014-07-30
AU2012325971A1 (en) 2014-04-17
EP2768506A4 (en) 2015-08-19
DOP2014000081A (es) 2014-07-15
WO2013059559A3 (en) 2013-11-14
TW201542567A (zh) 2015-11-16
CA2851801A1 (en) 2013-04-25
UY34406A (es) 2013-05-31
BR112014008727A2 (pt) 2017-04-25
AR088793A1 (es) 2014-07-10
EP2768506A2 (en) 2014-08-27
AU2012325971B2 (en) 2016-03-31
WO2013059559A2 (en) 2013-04-25
IL231894A0 (en) 2014-05-28
CN103957910A (zh) 2014-07-30

Similar Documents

Publication Publication Date Title
PE20141359A1 (es) Compuestos y metodos para mejorar las respuestas inmunitarias innatas
PE20210128A1 (es) Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20190624A1 (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2
PE20141371A1 (es) Compuestos heterociclicos y usos de los mismos
PE20140623A1 (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
PE20130339A1 (es) Compuestos heterociclicos y sus usos
PE20140015A1 (es) Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas
PE20141974A1 (es) Compuestos de heterociclilo
PE20140302A1 (es) Inhibidores del virus de la hepatitis c
PE20140412A1 (es) Inhibidores de glucosilceramida sintasa
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
AR065439A1 (es) Derivados de tiazoles 1,3 no condensados,composiciones farmaceuticas que los contienen y usos como agentes antivirales, en particular anti hiv.
PE20141828A1 (es) 6-alquinilo piridinas como mimeticos smac
PE20141280A1 (es) Inhibidores de aplicacion viral
PE20130576A1 (es) Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10
PE20061098A1 (es) COMPUESTOS IMIDAZO[1,2-a] PIRIDINILO COMO INHIBIDORES DE VEGF-R2
PE20110196A1 (es) 5-alquinil-pirimidinas
PE20120666A1 (es) Inhibidores de los virus flaviviridae
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA

Legal Events

Date Code Title Description
FA Abandonment or withdrawal